Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane.
10.3346/jkms.2004.19.4.547
- Author:
Jin Hee AHN
1
;
Sung Bae KIM
;
Tae Won KIM
;
Sei Hyun AHN
;
Sun Mi KIM
;
Jeong Mi PARK
;
Jung Shin LEE
;
Yoon Koo KANG
;
Woo Kun KIM
Author Information
1. Section of Hematology-Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. wkkim@amc.seoul.kr
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Breast Neoplasms;
Drug Therapy;
Antineoplastic Combined Chemotherapy Protocols;
Capecitabine;
Vinorelbine
- MeSH:
Adult;
Aged;
Anthracyclines/*therapeutic use;
Antineoplastic Agents/*therapeutic use/toxicity;
Breast Neoplasms/*drug therapy/*pathology;
Deoxycytidine/*analogs & derivatives/*therapeutic use/toxicity;
Drug Therapy, Combination;
Female;
Humans;
Middle Aged;
Neoplasm Metastasis;
Prodrugs;
Retrospective Studies;
Survival Rate;
Taxoids/*therapeutic use;
Treatment Outcome;
Vinblastine/*analogs & derivatives/*therapeutic use/toxicity
- From:Journal of Korean Medical Science
2004;19(4):547-553
- CountryRepublic of Korea
- Language:English
-
Abstract:
We have evaluated the efficacy and safety of the combination of capecitabine and vinorelbine in metastatic breast cancer (MBC) patients previously treated with anthracycline-and taxane-containing regimens. Between April 2000 and September 2002, 44 female MBC patients received oral capecitabine (1,250 mg/m(2) twice daily on days 114), and intravenous vinorelbine (25 mg/m2 on days 1 and 8) during each 3 weekchemotherapy cycle (median, 5 cycles/patient; total, 235 cycles). One patient achieved a complete response and 21 patients had partial responses, giving an overall response rate of 50% in the intention-to-treat analysis (95% CI, 35.0-65.0%). Median duration of response was 6.0 months (range 1.2-23.0 months). Patients were followed- up for a median of 16 months, with median progression-free survival being 5.3 months, and median overall survival being 17 months. Toxicities included grades III and IV neutropenia in 63 (26.8%) and 4 (1.7%) cycles, respectively, and grades II and III hand-foot syndrome in 12 (5.1%) and 4 (1.7%) cycles, respectively. Other nonhematologic toxicities were minimal and manageable. In conclusion, the combination of capecitabine and vinorelbine was effective and well tolerated in MBC patients even after treatment with anthracyclines and taxanes.
